| Literature DB >> 6232015 |
A Meheus, R Widy-Wirski, J D'Costa, E Van Dyck, R Delgadillo, P Piot.
Abstract
Gonorrhoea has become a problem in most parts of the world, and valid recommendations for treatment are important for control of the disease. In this study in Bangui, Central African Republic, 460 male patients with gonorrhoea were randomly assigned to treatment with either 4.0 x 10(6) units of procaine penicillin plus 1 g of probenecid, or 2 g of spectinomycin. Of these patients, 91% returned for follow-up; the failure rate was 4.8% with the penicillin schedule and 6.2% with spectinomycin (difference not statistically significant). Concomitant Chlamydia trachomatis infection was found in 5% of patients, and almost all of this group developed postgonococcal urethritis.Of the 460 patients, 7 (1.5%) were infected with penicillinase-producing Neisseria gonorrhoeae (PPNG) strains. Penicillin treatment failed in these cases, while spectinomycin was highly efficacious. The failure rate for penicillin was considerably higher in infections with strains that were less sensitive to penicillin in vitro. The failure rate for spectinomycin treatment was higher in patients who were infected with a strain that was highly sensitive to penicillin.It is concluded that, once PPNG strains have been found in a country, treatment of gonorrhoea should be based on an antibiotic that cures PPNG infections. Tetracycline can be used as second-line treatment, since it will also cure C. trachomatis infection, which is much less frequently associated with gonorrhoea in Africa than in industrial countries.Entities:
Keywords: Africa; Africa South Of The Sahara; Antibiotics; Central African Republic; Developing Countries; Diseases; Drugs; Evaluation; Examinations And Diagnoses; French Speaking Africa; Infections; Laboratory Examinations And Diagnoses; Middle Africa; Reproductive Tract Infections; Sexually Transmitted Diseases--men; Treatment
Mesh:
Substances:
Year: 1984 PMID: 6232015 PMCID: PMC2536286
Source DB: PubMed Journal: Bull World Health Organ ISSN: 0042-9686 Impact factor: 9.408